Jagsonpal Pharmaceutical surges as board approves Rs 40-cr buyback

The board approved the buyback of upto Rs 16 lakh equity shares, representing 2.39% of total outstanding equity shares. The buyback will be carried out at a price of Rs 250 per share, aggregating to a maximum outlay of Rs 40 crore.

The buyback price represents a premium of 39.74% over the previous day's closing price of Rs 178.90 on the BSE.

The company's promoter and promoter group shareholding stood at 67.2% prior to the buyback and is expected to increase to 68.9% post buyback.

Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.

The company's standalone net profit fell 8.4% to Rs 12.49 crore on 1.5% fall in net sales to Rs 72.95 crore in Q3 FY26 compared with Q3 FY25.

Powered by Capital Market - Live News